TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10516513

Group type: EXPERIMENTAL
Intervention: Tonometry with disposable latex cap (Group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tonometry without disposable latex cap (Group A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tonometry without latex cap in patients with IOP >/=20 mm Hg (Group A1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tonometry without latex cap in patients with IOP <20 mm Hg (Group A2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tonometry with latex cap in patients with IOP >/=20 mm Hg (Group B1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tonometry with latex cap in patients with IOP <20 mm Hg (Group B2)
Number of subjects: 80
Study: 7793203

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (n = 12)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Enflurane anaesthesia (n = 9)
Number of subjects: 21
Study: 1790403

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) 75 mg/day
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 31624422

Group type: EXPERIMENTAL
Intervention: Hf‐WBV (higher frequency, 5 times per week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lf‐WBV (lower frequency, 3 times per week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CG (control group, no training)
Number of subjects: 60
Study: 30431567

Group type: EXPERIMENTAL
Intervention: Shaft method to place biological mesh
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional tiling method
Number of subjects: 60
Study: 27208320

Group type: EXPERIMENTAL
Intervention: GLIPULIN (exenatide dosing before meals)
Number of subjects: 102

Group type: COMPARATOR
Intervention: BBI (rapid-acting insulin analogs)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: GLIPULIN
Number of subjects: 102

Group type: COMPARATOR
Intervention: BBI
Number of subjects: 102
Study: 25282565

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU/day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 22917598

Group type: EXPERIMENTAL
Intervention: Faith-based intervention
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Non-faith based intervention
Number of subjects: 450

Group type: COMPARATOR
Intervention: Information only control group
Number of subjects: 450
Study: 20464583

Group type: EXPERIMENTAL
Intervention: Frovatriptan (F) 2.5 mg
Number of subjects: 133

Group type: COMPARATOR
Intervention: Zolmitriptan (Z) 2.5 mg
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Frovatriptan (F)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Zolmitriptan (Z)
Number of subjects: 133
Study: 18580852

Group type: COMPARATOR
Intervention: TaqI A polymorphism of the DRD2 gene
Number of subjects: 119

Group type: COMPARATOR
Intervention: Atypical genotypes of the DAT1 gene
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: M235 polymorphism of the angiotensinogene gene
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 119
Study: 16003228

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5 g administered twice daily with CNI dose reduction or discontinuation (group 1: discontinuation, group 2: 50% reduction)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (CNI dose reduction or discontinuation without MMF)
Number of subjects: 27
Study: 12534449

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg day-1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg day-1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg day-1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg day-1)
Number of subjects: 64
Study: 10321660

Group type: EXPERIMENTAL
Intervention: Pressure ramp slope T 0.1 (0.1 secs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pressure ramp slope T 1.5 (1.50 secs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pressure ramp slope values (T 0.1 to T 1.5)
Number of subjects: 12
Study: 8542860

Group type: EXPERIMENTAL
Intervention: Injection speed of 10 seconds
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Injection speed of 20 seconds
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Injection speed of 30 seconds
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Injection speed of 1 minute (added group)
Number of subjects: 100
Study: 1787659

Group type: EXPERIMENTAL
Intervention: Halothane (0.5 vol.%) and nitrous oxide (65 vol.%) anesthesia with slight hyperventilation (PCO2 33 mmHg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Halothane-nitrous oxide anesthesia with varying PCO2 levels
Number of subjects: 20
Study: 7041769

Group type: EXPERIMENTAL
Intervention: New form of betahistine mesylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31183757

Group type: EXPERIMENTAL
Intervention: Education/training about pesticide use/adverse health effects in children
Number of subjects: 464

Group type: COMPARATOR
Intervention: No education/training about pesticide use/adverse health effects in children
Number of subjects: 464

Group type: COMPARATOR
Intervention: Grandparent as caregiver
Number of subjects: 464

Group type: COMPARATOR
Intervention: Annual income < 297 USD
Number of subjects: 464

Group type: COMPARATOR
Intervention: Insufficient health-related education/training
Number of subjects: 464
Study: 28727654

Group type: EXPERIMENTAL
Intervention: nHMF
Number of subjects: 153

Group type: COMPARATOR
Intervention: cHMF
Number of subjects: 153
Study: 26470880

Group type: EXPERIMENTAL
Intervention: Exercise intervention for 12 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 120
Study: 24171001

Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nonsurgical group
Number of subjects: 50
Study: 21371282

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy: 325 mg aspirin daily plus 75 mg clopidogrel daily
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Antiplatelet therapy: 325 mg aspirin daily plus placebo
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure target (<130 mmHg)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Usual systolic blood pressure target (130-149 mmHg)
Number of subjects: 3000
Study: 19621985

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 5 mg/kg infused over 24 h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17997363

Group type: EXPERIMENTAL
Intervention: Open‐irrigation‐tip catheter
Number of subjects: 70

Group type: COMPARATOR
Intervention: 8‐mm‐tip catheter
Number of subjects: 70
Study: 15124801

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (6 mg/kg BW, administered intravenously in six equal doses at 8 h intervals)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 87
Study: 11786156

Group type: EXPERIMENTAL
Intervention: WMS ≤16%
Number of subjects: 189

Group type: COMPARATOR
Intervention: WMS >16%
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: WMS ≤16% with ICD treatment
Number of subjects: 189
Study: 9844306

Group type: EXPERIMENTAL
Intervention: Olfactometry using natural coffee, aniseed, lemon, and mint oils
Number of subjects: 73
Study: 8271851

Group type: EXPERIMENTAL
Intervention: Immediate angioplasty
Number of subjects: 49

Group type: COMPARATOR
Intervention: Thrombolysis followed by conservative therapy
Number of subjects: 49
Study: 2574053

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenytoin (100 mg intravenously)
Number of subjects: 0
Study: 5298034

Group type: EXPERIMENTAL
Intervention: Ambilhar (non-metallic schistosomicide)
Number of subjects: 0
Study: 31053622

Group type: EXPERIMENTAL
Intervention: Parental self-assessment of discharge readiness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse assessment of family's emotional discharge readiness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse assessment of family's technical discharge readiness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nurse familiarity with the family at discharge
Number of subjects: 0
Study: 28284776

Group type: EXPERIMENTAL
Intervention: 20 and 35 mg/kg GHB
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 35 mg/kg GHB
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 47
Study: 26545298

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 498
Study: 23489776

Group type: EXPERIMENTAL
Intervention: Selenium 200 μg/day
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Selenium 400 μg/day
Number of subjects: 699

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 699
Study: 21733952

Group type: EXPERIMENTAL
Intervention: Cilostazol (low-dose 100 mg/d)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cilostazol (high-dose 200 mg/d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 19345784

Group type: EXPERIMENTAL
Intervention: Standardized performance of procedures immediately after training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized performance of procedures 1 year later
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized performance of procedures 2 years later
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scoring from routine participant testing and training
Number of subjects: 0
Study: 16988754

Group type: EXPERIMENTAL
Intervention: Losartan 100 mg + Amlodipine 5 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 21
Study: 15180116

Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulsed ultrasound
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transverse friction
Number of subjects: 30
Study: 11192339

Group type: EXPERIMENTAL
Intervention: Preventive occupational therapy (OT) for 9 months
Number of subjects: 0
Study: 9720932

Group type: EXPERIMENTAL
Intervention: Hepatic resection
Number of subjects: 123

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 123

Group type: COMPARATOR
Intervention: Intra-arterial infusion of doxorubicin
Number of subjects: 123
Study: 7999406

Group type: EXPERIMENTAL
Intervention: naproxen 1500 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: slow-release morphine 60 mg
Number of subjects: 20
Study: 3213896

Group type: EXPERIMENTAL
Intervention: Buflomedil 600 mg.d-1 in association with anti-edema drugs
Number of subjects: 14

Group type: COMPARATOR
Intervention: Anti-edema drugs only
Number of subjects: 14
Study: 30274958

Group type: EXPERIMENTAL
Intervention: Web-based complaint-directed mini-interventions (CDMIs)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group (no intervention, wait-listed)
Number of subjects: 329
Study: 28666299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Trimethoprim 80 mg and Sulfamethoxazole 400 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg
Number of subjects: 217
Study: 26140500

Group type: EXPERIMENTAL
Intervention: Breath-stacking technique using a lung volume recruitment bag
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mechanical insufflator-exsufflator (MI-E)
Number of subjects: 40
Study: 24262593

Group type: EXPERIMENTAL
Intervention: Fenoverine (100 mg three times a day)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Trimebutine (150 mg three times a day)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Fenoverine
Number of subjects: 197

Group type: COMPARATOR
Intervention: Trimebutine
Number of subjects: 197
Study: 21175925

Group type: EXPERIMENTAL
Intervention: Access to the Northwestern University Rotating Resident Curriculum (NURRC) during the first 2 weeks of the rotation (experimental group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No access to the NURRC during the first 2 weeks of the rotation (control group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: NURRC access
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Satisfaction with NURRC
Number of subjects: 54
Study: 18509579

Group type: COMPARATOR
Intervention: Land-based exercise
Number of subjects: 79

Group type: COMPARATOR
Intervention: Aquatic exercise
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study: 16548939

Group type: EXPERIMENTAL
Intervention: Maximal tailored behavioral treatment (baseline tailored brief motivational intervention, quit date behavioral skills counseling session, relapse prevention follow‐up session)
Number of subjects: 383

Group type: COMPARATOR
Intervention: Minimal treatment (brief advice using the National Cancer Institute's 4 As model)
Number of subjects: 383
Study: 14586916

Group type: EXPERIMENTAL
Intervention: Treadmill and overground walking program (30 minutes, 3 times a week for 4 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (low-intensity home exercise program and regular telephone contact)
Number of subjects: 29
Study: 10342818

Group type: EXPERIMENTAL
Intervention: Aggressive cholesterol lowering
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Moderate cholesterol lowering
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Low-dose warfarin
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1351

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 1351

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 1351
Study: 8728305

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg once daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nifedipine SR 20 mg twice daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 2185865

Group type: EXPERIMENTAL
Intervention: 3F/wk radiotherapy
Number of subjects: 734

Group type: COMPARATOR
Intervention: 5F/wk radiotherapy
Number of subjects: 734
Study: 92897

Group type: EXPERIMENTAL
Intervention: Birch, alder and hazel allergen in Allpyral
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Allpyral mixture plus all relevant tree pollens in aqueous extract
Number of subjects: 47

Group type: COMPARATOR
Intervention: No injections (Control group)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Immunotherapy (both treatment groups)
Number of subjects: 47
Study: 31775650

Group type: COMPARATOR
Intervention: Care coordination intervention involving practical nurses trained to assess medication risks and coordinating with pharmacists and physicians.
Number of subjects: 129

Group type: COMPARATOR
Intervention: Care coordination intervention
Number of subjects: 129
Study: 28876274

Group type: EXPERIMENTAL
Intervention: Modern Ring External Fixators
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internal Fixation
Number of subjects: 0
Study: 25119540

Group type: EXPERIMENTAL
Intervention: 0.25 % levobupivacaine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 55
Study: 25098557

Group type: EXPERIMENTAL
Intervention: Normal Protein (NP) breakfast (350 kcal, 13 g protein)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High Protein (HP) breakfast (350 kcal, 35 g protein)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Breakfast Skipping (BS)
Number of subjects: 20
Study: 21900837

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 233

Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: cfDNA EGFR mutation-positive subgroup
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: cfDNA EGFR mutation-negative subgroup
Number of subjects: 233
Study: 19909412

Group type: EXPERIMENTAL
Intervention: Buttonhole method of arteriovenous cannulation using the Biohole device
Number of subjects: 0
Study: 17466735

Group type: EXPERIMENTAL
Intervention: Single dose of botulinum toxin type A (Botox) (200 or 300 U)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 15983826

Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1, 80 mg on days 2 and 3)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 11997270

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (0.625 mg/d)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (medroxyprogesterone acetate 2.5 mg/d)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 9806688

Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine (1.5 mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1% bupivacaine (1.125 mL)
Number of subjects: 50
Study: 7714743

Group type: EXPERIMENTAL
Intervention: Formulation A (IPA/water/IPM; 11:7:1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Formulation B (ET/PG/IPM; 11:7:2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Formulation C (IPM/capmul)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Formulation A
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Formulation B
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Formulation C
Number of subjects: 9
Study: 3066620

Group type: EXPERIMENTAL
Intervention: Mazindol 2 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29022227

Group type: EXPERIMENTAL
Intervention: Contribution to family support
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Predictors of contribution
Number of subjects: 226
Study: 28682871

Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg/d)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 25627820

Group type: EXPERIMENTAL
Intervention: Goshajinkigan (GJG) 7.5 mg three times daily
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 21874353

Group type: EXPERIMENTAL
Intervention: Insulin analogues
Number of subjects: 47

Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 47
Study: 20709498

Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (0.2 mg/kg/5 min bolus followed by continuous infusion at 0.05, 0.10, or 0.20 mg/kg/h for 6h)
Number of subjects: 0
Study: 18166099

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 20845219

Group type: EXPERIMENTAL
Intervention: Increasing contextual interference practice schedule (initial blocked trials, followed by serial practice trials, and ended with random scheduling)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing contextual interference practice schedule (for basketball passes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked scheduling (control group for golf putting)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random scheduling (control group for golf putting)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked scheduling (control group for basketball passes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random scheduling (control group for basketball passes)
Number of subjects: 0
Study: 15735057

Group type: EXPERIMENTAL
Intervention: Diaphragms of patients with severe COPD
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Patients with severe COPD
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Muscle endothelial nitric oxide synthase in patients with severe COPD
Number of subjects: 19

Group type: COMPARATOR
Intervention: Muscle nitrotyrosine levels in patients with severe COPD
Number of subjects: 19
Study: 11219761

Group type: EXPERIMENTAL
Intervention: Maximum effort exerted by operators
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Power handtool operation
Number of subjects: 25
Study: 9778066

Group type: EXPERIMENTAL
Intervention: Ibutilide (1 mg)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 7888418

Group type: EXPERIMENTAL
Intervention: RBD-seasonal patients
Number of subjects: 42
Study: 3150319

Group type: EXPERIMENTAL
Intervention: Intranasal buserelin 400 micrograms three times daily for 6 months
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Post-treatment (6 months after stopping buserelin)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: During treatment with buserelin
Number of subjects: 13
Study: 30668196

Group type: EXPERIMENTAL
Intervention: Serum anti-Müllerian hormone (AMH) levels measured using VIDAS®
Number of subjects: 428

Group type: COMPARATOR
Intervention: AMH cutoff value of 42.1 pmol/L
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: AMH levels in PCOS women with three Rotterdam criteria or hyperandrogenism
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: AMH levels in PCOS
Number of subjects: 428
Study: 29936571

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-OA controls
Number of subjects: 28
Study: 27357222

Group type: EXPERIMENTAL
Intervention: Uncemented monoblock cruciate‐retaining (CR) tibial component (TM)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cemented NexGen Option CR tibial component
Number of subjects: 41
Study: 23962173

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60
Study: 22241819

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 212

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 212
Study: 19103558

Group type: EXPERIMENTAL
Intervention: Silymarin, 2 x 166 mg/day for 3 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for the first 3 months
Number of subjects: 32